🇪🇺 Zeposia in European Union

EMA authorised Zeposia on 20 May 2020

Marketing authorisation

EMA — authorised 20 May 2020

  • Application: EMEA/H/C/004835
  • Marketing authorisation holder: Bristol-Myers Squibb Pharma EEIG
  • Local brand name: Zeposia
  • Indication: Multiple sclerosis Zeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features. Ulcerative colitis Zeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
  • Status: approved

Read official source →

Zeposia in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in European Union

Frequently asked questions

Is Zeposia approved in European Union?

Yes. EMA authorised it on 20 May 2020.

Who is the marketing authorisation holder for Zeposia in European Union?

Bristol-Myers Squibb Pharma EEIG holds the EU marketing authorisation.